TREM2-Deficient Microglia
Overview
TREM2-deficient microglia refers to microglial cells lacking functional triggering receptor expressed on myeloid cells 2 (TREM2), a transmembrane immunoglobulin superfamily receptor. TREM2 is encoded by the TREM2 gene located on chromosome 6p21.1 in humans. Microglia are the primary resident immune cells of the central nervous system, and TREM2 serves as a critical sensor for pathological signals and cellular debris. Loss of TREM2 function fundamentally alters microglial responses to neurodegeneration, resulting in impaired clearance of amyloid-β, tau pathology, and cellular debris, while paradoxically affecting inflammatory gene expression patterns. TREM2-deficient microglia have become a major focus in neurodegeneration research following the discovery that rare TREM2 variants significantly increase Alzheimer's disease risk, and that TREM2 loss-of-function associates with neuropathological hallmarks characteristic of multiple neurodegenerative conditions.
Function/Biology
In healthy conditions, TREM2 functions as a pattern recognition receptor on microglial surfaces, binding to polyanionic ligands including phosphatidylserine on apoptotic cells, apolipoprotein E (ApoE), and bacterial lipopolysaccharides. TREM2 signaling occurs through association with the adaptor protein DAP12 (also called TYROBP), which contains immunoreceptor tyrosine-based activation motifs (ITAMs). This interaction recruits and activates Syk and Zap70 kinases, initiating intracellular signaling cascades that promote microglial survival, proliferation, and migration. Wild-type microglia expressing functional TREM2 efficiently phagocytose dead cells, protein aggregates, and debris—a process essential for maintaining CNS homeostasis.
TREM2-deficient microglia lose these ligand-binding capabilities and fail to activate downstream signaling pathways normally responsive to pathological stimuli. At the cellular level, this deficiency affects microglial morphology, with TREM2-deficient cells displaying reduced capacity for process extension and directional movement toward sites of pathology. Additionally, these cells show impaired survival and proliferation in response to damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) that would normally activate TREM2-dependent signaling.
Role in Neurodegeneration
TREM2 deficiency significantly exacerbates pathological features across multiple neurodegenerative diseases. In Alzheimer's disease models, TREM2-deficient microglia fail to efficiently clear amyloid-β plaques, leading to accelerated plaque accumulation and enhanced neuroinflammation. The impaired phagocytic capacity results in increased plaque burden and altered microglial clustering around amyloid deposits, with remaining microglia showing activation of pro-inflammatory transcriptional programs.
In tau pathology contexts, TREM2 deficiency impairs microglial response to tau-laden neurons, compromising debris clearance and contributing to tau propagation. Studies of TREM2-deficient mice crossed with tauopathy models reveal exacerbated tau accumulation and neurodegeneration compared to wild-type controls.
TREM2 dysfunction has also been implicated in frontotemporal dementia, Parkinson's disease, and amyotrophic lateral sclerosis pathogenesis. In these contexts, TREM2 deficiency dysregulates the microglial response to disease-specific pathology, promoting neuroinflammatory cascades that accelerate neuronal loss. The deficiency affects microglial transcriptional programs, reducing expression of homeostatic genes while altering inflammatory gene signatures in complex, disease-context-dependent patterns.
Molecular Mechanisms
TREM2 deficiency disrupts multiple signaling pathways simultaneously. Loss of DAP12-mediated Syk activation impairs phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathway activation, reducing microglial phagocytic capacity. Additionally, TREM2-DAP12 signaling normally suppresses NF-κB-dependent pro-inflammatory gene expression; its absence results in dysregulated inflammatory responses.
At the transcriptomic level, TREM2-deficient microglia show altered expression of genes associated with lipid metabolism, phagocytosis, and survival. Specifically, downregulation of genes like Apoe, Csf1, and Igf1 impairs metabolic adaptation and microglial support functions. Simultaneously, some inflammatory gene programs become hyperactive, creating a microglial phenotype characterized by both impaired neuroprotective capacity and dysregulated inflammation.
Clinical/Research Significance
TREM2 variants represent the most significant genetic risk factor for late-onset Alzheimer's disease identified outside the APOE locus. Rare coding variants increase disease risk by three- to five-fold, while common variants confer more modest risk. This discovery has revolutionized understanding of neuroinflammation's role in neur
See Also
- [Microglia Depletion and Repopulation Therapy](/wiki/therapeutics-microglia-depletion-repopulation) — expressed_in